Status:
COMPLETED
Caduet in an Untreated Subject Population
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Hypertension
Dyslipidemia
Eligibility:
All Genders
21+ years
Phase:
PHASE4
Brief Summary
The purpose of this study is to determine if Caduet will lower blood pressure to \<140/90 mmHg and lower LDL Cholesterol to \<100 mg/dL in subjects with hypertension and dyslipidemia who are not curre...
Eligibility Criteria
Inclusion
- Subjects who were recently diagnosed with both hypertension and dyslipidemia and who are not yet taking any medications for these conditions OR subjects with both hypertension and dyslipidemia who were previously treated with antihypertensive and/or lipid lowering medications but discontinued these medications for at least 3 months prior to the Screening visit.
- SBP 140-169 mmHg and/or DBP 90-105 mmHg, LDL-C 110-160 mg/dL
Exclusion
- Subjects with a history of MI, angina, coronary artery bypass or intra-coronary interventions, stroke, TIA, CHF or cardiomyopathy requiring treatment.
- Subjects with a known history of Type I or Type 2 Diabetes Mellitus or a fasting blood glucose \> 126 mg/dL at the Screening visit.
Key Trial Info
Start Date :
June 1 2006
Trial Type :
INTERVENTIONAL
End Date :
September 1 2007
Estimated Enrollment :
220 Patients enrolled
Trial Details
Trial ID
NCT00332761
Start Date
June 1 2006
End Date
September 1 2007
Last Update
January 27 2021
Active Locations (34)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Jonesboro, Arkansas, United States, 72401
2
Pfizer Investigational Site
Little Rock, Arkansas, United States, 72204
3
Pfizer Investigational Site
Garden Grove, California, United States, 92843
4
Pfizer Investigational Site
Long Beach, California, United States, 90806